BCAX: Bicara Therapeutics Inc Company Value to Net Income

Bicara Therapeutics Inc - graphic logo of issuer BCAX

Bicara Therapeutics Inc. relies on investment capital to conduct medical trials. The price-to-earnings ratio reflects the asset's current volatility, where the value of -2.90 determines this level. Growth is driven by partnerships with pharma behemoths to develop antibodies. Meanwhile, the humanitarian status of these developments minimizes the impact of global political risks on the business.

Price to Earnings Ratio: Bicara Therapeutics Inc. (BCAX) for 06/05/2025 - 11/15/2026

Comprehensive metric breakdowns and analytics for Bicara Therapeutics Inc (BCAX)

- share price and expert price forecast:
Summary company analysis:Bicara Therapeutics
Flagship merchandise of Bicara Therapeutics

Professional selection of sustainable assets is based on comparing market capitalization with actual profit generation to exclude overvalued securities. By analyzing the annual P/E of the company, an investor sees the ratio of the share price to net income, which in the case of Bicara Therapeutics Inc. (BCAX) reflects the business's ability to cover high costs for specialized medical logistics and cold chain compliance during drug delivery.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|PSNL - P/E Multiple|Erasca Corp (ERAS) - Price to Earnings Ratio|Delcath - Company Value to Net Income|YMAB (Y-mAbs Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Aura Biosciences, Inc. AURA|P/E Multiple CADL|P/E Multiple Accuray (ARAY)|Price to Earnings Ratio SELLAS Life Sciences Group Inc. SLS|ACTU - Price to Earnings Ratio|CTOR: Price to Earnings Ratio|Company Value to Net Income HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Fate Therapeutics Corp (FATE)|Price to Earnings Ratio WHWK|Price to Earnings Multiple TCRX (TScan Therapeutics, Inc.)|P/E Multiple CSBR|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV